Legal Troubles for TransMedics and Pacira: Investors File Lawsuits
New York, Wednesday, 18 June 2025.
Investors have filed lawsuits against TransMedics Group and Pacira BioSciences, alleging misleading statements that impacted stock decisions. These lawsuits highlight key concerns in biotech investment practices.
Background on TransMedics Group Lawsuit
On February 14, 2025, a lawsuit was filed against TransMedics Group, Inc. (NASDAQ:TMDX), alleging securities law violations. The plaintiffs accused TransMedics of utilizing kickbacks, fraudulent billing practices, and coercive tactics to boost revenue. Furthermore, the company is alleged to have engaged in unsafe practices while failing to disclose significant safety issues, which heightened regulatory scrutiny risks [1][2].
Court Developments and Investor Position
In a recent development, the court appointed a lead plaintiff and counsel on May 22, 2025, indicating the legal proceedings’ progression against TransMedics Group [1]. Shareholders who purchased shares before February 2023 are urged to contact the Shareholders Foundation for information on their legal options as the case unfolds [2].
Pacira BioSciences Under Scrutiny
Simultaneously, a lawsuit filed on January 13, 2025, against Pacira BioSciences, Inc. (NASDAQ:PCRX) claims the company issued misleading statements regarding the patent protection of its principal product, Exparel. The accusations have brought forth significant investor concerns regarding Pacira’s revenue stream stability, as Exparel contributes to a sizable portion of the company’s income [1][2].
Legal and Market Implications
These lawsuits signal broader challenges for biotech investors, emphasizing the need for thorough due diligence and transparency in corporate dealings. As both cases are actively developing—the Pacira case recently saw a lead plaintiff appointed on May 21, 2025—it underscores ongoing market turbulences and the critical nature of informed investment strategies in the biotech field [2][3].